A recent study sheds light on a previously unrecognized pathway linking a genomic modification unique to primates to the onset of neurodegenerative disorders, including dementia. This groundbreaking research underscores the critical role of specific DNA sequences, known as Alu elements, which are prevalent in human and primate genomes but absent in conventional animal models like mice. The investigation reveals how an Alu-mediated gene deletion can trigger a cascade of cellular dysfunctions, culminating in neuronal damage characteristic of dementia.
The findings, published by a collaborative research team from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), highlight the utility of human stem cell-derived brain organoids in deciphering complex disease mechanisms that are otherwise challenging to replicate. This approach allowed scientists to model a genetic alteration found in patients with hereditary spastic paraplegia, a condition sometimes co-occurring with cognitive decline and dementia, providing a clearer understanding of the underlying pathological processes and potential therapeutic targets.
Primate-Specific Genetic Anomaly Drives Cellular Dysfunction
The research team at KRIBB meticulously investigated the implications of a primate-specific genomic variation involving Alu elements. These short interspersed nuclear elements, constituting approximately 10% of the human genome, can lead to genetic deletions through abnormal recombination. The study focused on a deletion within the SPAST gene, which is associated with hereditary spastic paraplegia. Notably, patients with extensive deletions in this gene often exhibit not only motor symptoms but also cognitive impairment and dementia, a phenomenon that has long puzzled scientists. The absence of Alu elements in standard animal models, such as mice, has historically impeded a comprehensive understanding of how these genetic changes contribute to human brain disorders.
By leveraging human brain organoids engineered to mimic a patient-specific SPAST gene deletion, the scientists observed the formation of an aberrant fusion transcript involving the deleted SPAST gene and the adjacent SLC30A6 gene. This novel genetic construct led to a significant reduction in the levels of ZnT6, a crucial zinc transporter produced by SLC30A6 and localized in the Golgi apparatus. The compromised ZnT6 function resulted in an abnormal accumulation of zinc within the cellular cytoplasm, disrupting the delicate balance of intracellular zinc. This imbalance, in turn, triggered the fragmentation of the Golgi apparatus, a vital organelle responsible for protein and lipid processing and transport, setting the stage for neurodegenerative pathology.
Zinc Dysregulation and Golgi Fragmentation Lead to Neurodegeneration
The progressive cellular disruptions observed in the brain organoids, stemming from the primate-specific genetic anomaly, culminated in pronounced neurodegenerative abnormalities. The study documented an approximate tenfold increase in amyloid-beta aggregation, a recognized hallmark of Alzheimer's disease, and a fourfold rise in apoptotic neurons compared to control samples. These findings strongly implicate the Alu-mediated SPAST gene deletion, the subsequent ZnT6 deficiency, and the resulting Golgi fragmentation in the pathogenesis of dementia-related neurodegeneration. This discovery provides a direct link between a unique human genomic feature and the complex mechanisms underlying brain diseases, expanding our understanding beyond previously identified pathways.
Further experimental interventions demonstrated the therapeutic potential of addressing this newly identified pathway. Researchers successfully mitigated neuronal damage by deploying a zinc-specific chelator to reduce excess intracellular zinc or by preventing Golgi fragmentation. These interventions not only restored Golgi structure but also decreased amyloid-beta levels and alleviated other pathological features, including lipid abnormalities. The observed improvements highlight the ZnT6–Golgi axis as a promising therapeutic target for neurodegenerative conditions driven by structural genetic variants. Additionally, analyses of postmortem brain tissue from Alzheimer's patients revealed an association between abnormal ZnT6 expression and Golgi fragmentation, with one sample even containing the specific SPAST–SLC30A6 fusion transcript, suggesting the relevance of these findings to more prevalent forms of dementia and paving the way for future research into their broader clinical applicability.